Hypophysitis, most seen with anti-CTLA-4 therapy, is thought to result from a combination of type II hypersensitivity reactions involving IgG or IgM antibodies and T cell-mediated type IV hypersensitivity. Here, CTLA4 is linked to hypophysitis.